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Abstract
Background: The prevalence of overweight is increasing globally and has become a serious health problem. Low-grade
chronic inflammation in overweight subjects is thought to play an important role in disease development. Novel tools to
understand these processes are needed. Metabolic profiling is one such tool that can provide novel insights into the impact
of treatments on metabolism.
Methodology: To study the metabolic changes induced by a mild anti-inflammatory drug intervention, plasma metabolic
profiling was applied in overweight human volunteers with elevated levels of the inflammatory plasma marker C-reactive
protein. Liquid and gas chromatography mass spectrometric methods were used to detect high and low abundant plasma
metabolites both in fasted conditions and during an oral glucose tolerance test. This is based on the concept that the
resilience of the system can be assessed after perturbing a homeostatic situation.
Conclusions: Metabolic changes were subtle and were only detected using metabolic profiling in combination with an oral
glucose tolerance test. The repeated measurements during the oral glucose tolerance test increased statistical power, but
the metabolic perturbation also revealed metabolites that respond differentially to the oral glucose tolerance test.
Specifically, multiple metabolic intermediates of the glutathione synthesis pathway showed time-dependent suppression in
response to the glucose challenge test. The fact that this is an insulin sensitive pathway suggests that inflammatory
modulation may alter insulin signaling in overweight men.
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Introduction
The low-grade inflammatory state often seen in overweight
subjects is thought to play an important role in lifestyle associated
disease development. This inflammatory state has been associated
with cardiovascular diseases [1], diabetes, insulin resistance [2]
and cancer [3]. Since the early 1990s [4], considerable effort has
been made to discover and validate biomarkers with diagnostic or
prognostic utility for lifestyle associated diseases [5,6,7]. Metabo-
lites such as cholesterol, fasting glucose and homocysteine have
long been used as biomarkers. Genomic – based technologies such
as metabolic profiling provide a new means to explore the
combination of multiple metabolites as a biomarker, which may
allow for more precise outcome predictions. Alternatively, such a
biomarker may provide a more comprehensive insight into
pathophysiological processes not previously attainable with
traditional biomarkers [8,9,10]. These markers should respond
to nutritional and pharmaceutical interventions in order to be
evaluated.
The main focus of the present study was to demonstrate and
quantify the consequence of using diclofenac to reduce inflam-
mation and its effect on metabolism. Subsequently, the study was
geared to identify multiple metabolites to be used as a potential
biomarker. Diclofenac acts as a non-selective inhibitor of the
enzymes cyclooxygenase-1 and -2. Cyclooxygenases catalyze
among other things the formation of prostaglandins that act as
messenger molecules in inflammation. Metabolic profiling has
been shown to be a valuable tool to quantify nutritional metabolic
homeostasis and disease mechanisms associated with metabolic
stress and metabolic syndrome [11,12,13]. Liquid and gas
chromatography mass spectrometric methods (LC-MS and GC-
MS) were used to detect high and low abundant metabolites in
plasma to obtain a comprehensive picture of metabolic changes
induced by a mild anti-inflammatory drug intervention. A total of
343 plasma metabolites were quantified, of which 204 could be
identified, spanning diverse chemical classes (Table S1). The
metabolic profiling approach was not only applied in fasting
(homeostatic) conditions, but also at multiple time points during an
oral glucose tolerance test (OGTT). This approach is based on the
concept that the resilience of the system can be assessed after
challenging or perturbing a homeostatic situation. Plasma
metabolic profiling combined with a glucose challenge has already
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and individuals with an impaired glucose tolerance [14]. Applying
a metabolic perturbation and metabolic profiling may help identify
a set of metabolites that predict differences in the responses
between treatment groups to the oral glucose tolerance test. A
similar set of metabolites might then provide novel insight into the
interplay between metabolic and inflammatory processes and
provide candidate biomarkers to be applied in (intervention)
studies aimed at lifestyle associated diseases.
Materials and Methods
Ethics statement
The study was approved by the Medical Ethics Committee of
the University Medical Centre of Utrecht (May 17, 2005). In total,
fifty subjects gave written informed consent after being informed
about the study, both verbally and in writing.
Subjects and study design
The study was conducted at TNO Quality of Life (Zeist, the
Netherlands). Overweight and mildly obese men (Body Mass
Index (BMI) between 25.1 and 34.0 kg/m2) were recruited from a
pool of volunteers. All fifty subjects completed a questionnaire on
medical history and were physically examined. Blood and urine
were collected after an overnight fast for routine analysis. In
addition, plasma hsCRP levels were determined.
Subjects met the following in- and exclusion criteria. Smokers,
subjects who reported that they were trying to lose weight or who
were on a medically prescribed diet and subjects with allergy or
hypersensitivity for non-steroidal anti-inflammatory drugs were
excluded from participation. Additionally, subjects who were on
medication that may have interfered with parameters to be
measured or with diclofenac treatment or subjects who, based on
anamnesis, were not suitable to receive diclofenac treatment
(history of current gastro-intestinal diseases including bleeding,
ulcer or perforation, history of stroke, history of current significant
haematological disorders, any significant hepatic, renal or
cardiovascular disease, asthma) or subjects with a history of
medical or surgical events that may have affected the study
outcomes were not included. Based on these criteria, 25 subjects
were eligible. Of the 25 eligible subjects, the 5 subjects with the
lowest CRP values were not included in the study. Levels of
hsCRP of the included subjects ranged from 0.41–9.72 mg/L (see
also Table 1).
The study was designed as a double blind, randomized, parallel
trial, in which subjects were treated with diclofenac (n=10) or
placebo (n=10). Randomization of subjects to treatment groups
was restricted by hsCRP, body mass index (BMI), fasting glucose
and age. The result is a homogeneous division of these parameters
over the two treatment groups at the start of the study (see Table 1).
Subjects consumed one capsule (placebo or 50 mg diclofenac)
approximately one hour before breakfast, lunch and dinner for 9
days. Subjects were instructed to keep to their habitual diet during
the study. One person dropped out on the first day of the study for
study unrelated reasons. Nineteen men completed the study. Their
subject characteristics are presented in Table 1. Prostaglandin E2
concentrations were used as a readout for diclofenac treatment
and showed a significant reduction in subjects treated with
diclofenac (p=0.02). Prostaglandin E2 concentrations were
unchanged in subjects treated with placebo demonstrating a
modulation of the inflammatory status in diclofenac treated
subjects (Table 2).
Blood samples were taken after an overnight fast on days 0, 2, 4,
7 and 9. Subjects underwent an oral glucose tolerance test
(OGTT) on day 0 and day 9. Blood samples were taken just before
(0 minutes) and 15, 30, 45, 60, 90, 120 and 180 minutes after the
administration of the glucose solution (75 grams). Samples were
analyzed for glucose and insulin for which the incremental area
under the response curves (AUC) was calculated. Table 2 shows
the characteristics of these parameters. No significant changes
Table 1. Demographic data of subjects that completed the study (n=19) at screening; mean6SD (range).
All (n=19) Placebo treatment (n=10) Diclofenac treatment (n=9)
Age (years) 43615 41616 (19–60) 45615(21–58)
Body weight (kg) 93.568.0 93.569.3 (81.1–105.2) 93.566.9 (85.2–104.4)
Height (m) 1.8260.08 1.8260.10(1.69–1.96) 1.8360.07 (1.70–1.92)
BMI (kg/m
2) 28.161.2 28.161.0 (26.7–29.3) 28.161.5 (26.1–30.9)
hs-CRP (mg/L) 2.2262.33 2.0861.88 (0.41–6.35) 2.3762.87(0.64–9.72)
Fasting glucose (mmol/L) 6.060.5 5.960.5 (5.2–7.1) 6.060.6 (5.0–6.8)
Fasting insulin (mU/L) 13.468.1 13.468.6 (5.1–26.8) 13.368.1 (3.3–26.6)
doi:10.1371/journal.pone.0004525.t001
Table 2. Characteristics of prostaglandin E2 and OGTT parameters (insulin and glucose) measured at start and end of treatments.
AUC=area under the curve.
Placebo Diclofenac
Day 0 Mean (st dev) Day 9 Mean (st dev) Day 0 Mean (st dev) Day 9 Mean (st dev)
PGE2 [pg/mL] 56.5 (7.7) 60.8 (11.0) 55.3 (11.9) 48.9 (10.6)
AUC glucose [mmol*min/L] 409 (238) 306 (197) 365 (255) 262 (199)
AUC insulin [mU*min/L] 8986 (5356) 8935 (4821) 12140 (12037) 9965 (9078)
doi:10.1371/journal.pone.0004525.t002
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design and time points at which metabolic profiling measurements
were done.
Plasma PGE2, insulin and glucose measurements
PGE2 was determined using the Prostaglandin E2 [
125I] Biotrak
assay system (Amersham Biosciences, UK) with modifications. In
short, PGE2 in samples was derivatized to the methyl oximate
derivative. The resulting solution was further diluted (final dilution
5 times) in PBS and partly assayed. The assay consists of
incubation of the oximated sample PGE2, the
125I-labelled
PGE2, and a PGE2 specific antibody. After incubation, the
Amerlex-M reagent is added and the free and bound
125I labeled
PGE2 separated using centrifugation. The resulting bound
radioactivity in the pellet is determined using a gamma-counter.
Serum glucose concentrations were measured by using a
commercial test kit (Roche diagnostics GmbH, Mannheim,
Germany) on a Hitachi 911 automatic analyzer (Hitachi
Instrument Division, Ibaraki-ken, Japan), with intra-assay CVs
that ranged between 0.7% and 0.9%, depending on the
concentration. Serum insulin concentrations were measured using
an AIA-600 Immunoassay Analyzer (Tosoh Corporation,
Toyama, Japan), with intraassay CVs that ranged between 4.3%
and 5.8%, depending on the concentration.
Metabolic profiling measurements
LC-MS of lipids and fatty acids. Plasma lipids and free
fatty acids (FFA) were analyzed with electrospray LC-MS [15,16].
The instrument used was a Thermo LTQ equipped with a
Thermo Surveyor HPLC pump. Data were acquired by scanning
the instrument form m/z 300 to 1200 at a scan rate of
approximately 2 scans/s. The FFA LC-MS platform employs
the same HPLC conditions as the lipid method except for the
gradient. Detection of FFA is performed in negative ion mode, and
lipids are measured in positive ion mode. Taken together the two
methods can measure approximately 200 different identified lipids
and FFA.
In summary, 10 ml of plasma was extracted with 300 mlo f
isopropanol containing several internal standards (IS: C17:0 lyso-
phosphatidylcholine, di-C12:0 phosphatidylcholine, tri-C17:0
glycerol ester, C17:0 cholesterol ester and heptadecanoic acid
(C17:0)). Each extract was injected three times (10 ml), once for the
LC-MS FFA platform and two times for the LC-MS lipid
platform. Furthermore, a quality control (QC) sample was
prepared by pooling of plasma from all subjects. The pool was
divided into 10 ml aliquots that were extracted the same as the
study samples. The QC samples were placed at regular intervals in
the analysis sequence (one QC after every 10 samples). The QC
samples served two purposes. The first is a regular quality control
sample to monitor the LC-MS response in time. After the response
has been characterized, the QC samples were used as standards of
unknown composition to calibrate the data [17].
In the plasma samples, the 6 dominant lipid classes observed
with these two methods are the Lyso-phosphatidylcholines (IS
used: C17:0 lyso-phosphatidylcholine), Phosphatidylcholines (IS
used: di-C12:0 phosphatidylcholine), Sphingomyelines (IS used:
di-C12:0 phosphatidylcholine), Cholesterolesters (IS used: C17:0
cholesterol ester), Triglycerides (IS used: tri-C17:0 glycerol ester),
and free fatty acids (IS used: C17:0 FFA). In addition to these
lipids, the extracts also contain minor lipids, but these were either
not detected (concentration too low relative to very abundant
lipids like phosphatidylcholines and triglycerides) or they were not
included in data processing. The LC-MS lipid and LC-MS FFA
data were processed using the LC-Quan software (Thermo).
LC-MS polar. Polar plasma metabolites were analyzed using
LC-MS after derivatization (butylation). The metabolites were
extracted from 10 ml plasma with 200 ml methanol containing
internal standards (deuterated amino acids). After the methanol
evaporated, the extract was dissolved in 100 ml n-butanol
containing 4 M/l hydrochloric acid and heated to 65uC for
Figure 1. Overview of study design, time points at which metabolome was measured and multivariate data analyses. To determine
metabolites that were modulated by the diclofenac treatment the following multivariate data comparisons were performed to identify metabolites
that were modulated by the diclofenac treatment: a) PLS-DA on metabolic profiling data from day 9 subtracted by metabolic profiling data from day
0, on fasted plasma samples; b) n-PLS-DA on metabolic profiling data from day 0, 2, 4, 7 and 9, on fasted plasma samples; c) n-PLS-DA on metabolic
profiling data from day 9 subtracted by metabolic profiling data from day 0, using the fasted plasma samples and the samples after glucose
administration, thus metabolic profiling data on 0, 15, 30, 45, 60, 90, 120 and 180 minutes after glucose administration. The multivariate data
comparisons from a-c were performed per metabolite platform, thus multivariate models were created for GC-MS global, LC-MS polar, LC-MS lipids
and LC-MS free fatty acids data.
doi:10.1371/journal.pone.0004525.g001
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0.1% formic acid in water, and 10 ml was injected for LC-MS
analysis using a Thermo LTQ equipped with an ESI interface and
a Surveyor HPLC system. QC samples, prepared from pooled
plasma, were analyzed after every 6
th study sample. The mass
spectrometer was operated in positive ion mode and data were
acquired by scanning from m/z 125 to 1000 at approximately 2
scans/s. The HPLC method consisted of an Intersil ODS 3
column (10063 mm id) in combination with an acetonitrile
gradient (5 to 80% in 20 min at a flow of 0.3 ml/min) in 0.1%
formic acid.
Data were processed with TNO comprehensive peak picking
software (IMPRESS, [18,19] to find consistent features in the LC-
MS files. These features, after de-isotoping, were used for data
processing with Thermo LC-Quan software.
GC-MS global. The GC-MS method used for analyzing a
broad range of metabolites was identical to the method reported
for microbial metabolic profiling [20], except for the sample type.
Plasma samples (100 ml) were extracted with methanol and after
evaporation the metabolites were derivatized (oximation and
silylation). QC samples, prepared from pooled plasma, were
analyzed after every 10
th study sample.
Performance of metabolic profiling platforms. The
performance of the applied metabolic profiling platforms is
assessed through the frequent analysis of the QC sample [17].
This QC sample, prepared by pooling selected study samples,
represents the full biochemical diversity of the study samples and
allows the calculation of the analytical precision for all metabolites
measured. The QC sample data is also used to correct systematic
errors (e.g. batch to batch response differences) by a single point
calibration model. Typically, this procedure offers excellent
precision for a large majority of metabolites (e.g. 50% of the
metabolites have an RSD of less than 10%, 75% with an RSD less
than 20%). Metabolites with very high imprecision e.g.
RSD.50%, were removed from the data unless large
differences between treatment groups were observed.
Furthermore, method performance was carefully monitored
using multiple internal standards (5 to 10 depending on method,
including analogues, 2H and 13C labeled metabolites) and
duplicate analysis of samples. The metabolite data used for
statistical data analysis in this study met all of our quality
requirements.
Preprocessing of metabolic profiling data
Data for each subject were corrected for the recovery of the IS
for injection. Batch to batch differences in data were removed by
synchronizing medians of QC-samples per batch. For all
platforms, duplicate measurements were combined into a single
measurement. When both analytical duplicates had a zero value
or when both had a non-zero value, measurements were
averaged. The single value was taken when only one of the
duplicates was above zero [15]. To avoid trivial results, data were
additionally optimized by removing glucose-related metabolites
and IS-isotopes in the LC-MS polar data and two glucose
metabolites in the GC-MS global data set. The correlation
between these glucose peaks and glucose measured by a
commercial test kit (Roche Diagnostics GmbH, Mannheim,
Germany) on a Hitachi 911 automatic analyzer (Hitachi
Instrument Division, Ibaraki-ken, Japan) was 0.97 and 0.98
respectively. Finally, the LC-MS FFA data set contained 14
metabolites, the LC-MS Lipids data set consisted of 61
metabolites, 120 metabolites were included in the LC-MS polar
data set and the GC-MS data set contained 137 metabolites.
Multivariate analysis of metabolic profiling data
Two-way analysis: PLS-DA. Partial Least Squares
Discriminant analysis (PLS-DA) [21] was used to identify
metabolites that differ in their change between day 0 and day
9 in fasted conditions between treatment groups (Figure 1,
analysis a). In PLS-DA, a Y-variable containing class
membership information is correlated to a data matrix (X-
block). The subjects who received the placebo treatment were
assigned to class ‘0’ and the subjects who received diclofenac
were assigned to class ‘1’. Since the interest was in intra-
individual differences between day 0 and day 9, the X-block was
defined for each metabolite platform by subtracting the day 0
values from the day 9 values, which removed differences in
baseline.
Two-way analysis: model validation and
optimization. Cross-validation was used to validate the
PLS-DA models, using a ‘leave-one-out’ cross-validation
scheme [22]. Data of one subject were left out in the first
cross-validation step, a PLS-DA model was built, and the
treatment class membership of the subject that was left out was
predicted. This was repeated until all 19 subjects were left out
once. The error rate of the model was determined by comparing
the original class membership and the predicted one. The
optimal number of LVs was determined based on the minimum
value of this error rate. The final fit of the model was made
using this number of optimal LVs.
PLS-DA models for which an error rate was found below 35%
were optimized by performing metabolite selection based on a
jackknife approach [22]. Data of one subject were left out and a
PLS-DA model was made using the same number of LVs that was
used for the final model. This was repeated until all 19 subjects
were left out once. This resulted in 19 sets of regression
coefficients, of which the standard deviation was used to determine
the relative standard devations (RSDs) of each regression
coefficient. Only those metabolites that had a RSD of less than
50% were included in a new data set. This set was used to build a
second PLS-DA model. Metabolites that contributed to treatment
differences were identified based on absolute regression coefficients
of this second model.
Three-way analysis: n-PLS-DA. To identify metabolites
that differed in changes over time between the treatment groups, it
was necessary to discriminate between the time and the metabolite
information. Basic multivariate data analysis tools like Principal
Component Analysis (PCA; [23,24,25,26]) and Partial Least
Squares Discrimant analysis (PLS-DA; [21]) are not sufficient to
analyze the data sets, since these methods do not separate the time
factor from the metabolites. Therefore, the multi-way
generalization of these two-way techniques, nPLS-DA, [27,28]
was used for the analyses. A so called 3-way matrix was created,
having size 196J6T where J is equal to the number of metabolites
of a particular platform and T is equal to the number of time
points, which were either the days 0, 2, 4, 7, and 9 (Figure 1,
analysis b) or the time points after glucose administration on day 0
and 9 (Figure 1, analysis c). In order to focus the analysis on
changes over time within a subject, the day 0 data were subtracted
from the day 9 data.
The GC-MS global and LC-MS polar data sets were centered
across subjects and followed by scaling within the metabolite-mode
J, whereas the LC-MS lipids and fatty acids data sets were only
centered across subjects. The centering step was performed to
remove constants between the subjects, whereas scaling within the
metabolite mode resulted in standardized metabolites. By
performing the scaling step after the centering step, the prior
centering remained unaffected [29,30,31].
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optimization. Cross-validation was used to validate the nPLS-
DA models, using a ‘leave-one-subject-out’ cross-validation
scheme. Data of one subject (all measurements for all
metabolites for one subject) were left out in the first cross-
validation step, an nPLS-DA model was built using data of the
remaining subjects, and the treatment class membership of the
subject that was left out was predicted. This was repeated until all
19 subjects were left out once. The error rate of the model was
determined by comparing the original class membership and the
predicted one. The optimal number of LVs of the nPLS-DA
model was determined based on the minimum value of this error
rate.
In order to optimize the nPLS-DA models, metabolite selection
has been performed using a jackknife approach. Data of one
subject (all measurements for all metabolites for one subject) were
left out and an nPLS-DA model was made using the same number
of LVs that was used for the final model. This was repeated until
all 19 subjects were left out once. This resulted in 19 sets of
regression coefficients, of which the standard deviation was used to
determine the RSD’s of each regression coefficient for each
metabolite and each time point. A second nPLS-DA model was
build using only those metabolites which showed relatively
constant regression coefficients over time.
A permutation test was performed to test whether the treatment
differences were indeed true differences similar as described by
Bijlsma et al [15]. Therefore, the Y-variable containing class
membership information was randomized a 10000 times. For each
random vector, a multilevel nPLS-DA model was made using the
same (optimal) number of LVs as determined previously. For every
nPLS-DA model built, a sum of squares between/sum of squares
within ratio (B/W) was calculated for the class assignment
predictions. These distributions of random class assignments can
be plotted in a histogram and compared to ratio for the original
model. The model is classified as ‘bad’ if the B/W of the model is
plotted in the lower half of the B/W distribution of random class
assignments; the model is classified as ‘moderate’ if the B/W of the
model is plotted in the upper half of the B/W distribution of
random class assignments; the model is classified as ‘good’ if the B/
W of the model is larger than the B/W distribution of random
class assignments.
All analyses were performed using Matlab Version 7.0.4 R14
(The Mathworks, Inc.) and the n-way toolbox version 2.11 [32].
Annotation and Identification of metabolites
ThenPLS-DAmodelresultedinaregressionmatrixofsizeJ*6K,
in which J* is the number of metabolites after variable selection. To
determine the variables which contributed most to treatment
differences, the regression coefficients were sorted by their absolute
value in descending order per time point. Since the regression
coefficients decreased gradually between the highest and the lowest
value due to the use of autoscaled data, there was no sharp cutoff.
Therefore, for each time point the first ten peaks with unknown
identity were selected and used for metabolite identification.
Metabolites were annotated using an in-house metabolite
database containing retention time information, MS spectra (EI
for GC-MS data), MS/MS spectra (LC-MS) and accurate mass
data (LC-MS) of reference substances. The confidence of
identification is 100% unless indicated otherwise. Accurate mass
MS and MS/MS data of reference substances and metabolites in
the study samples were acquired using Thermo LTQ-FT and
Thermo LTQ-Orbitrap instruments.
Biological interpretation of metabolic profiling data
For each metabolite, the mean treatment effect difference
between day 9 and day 0 during the OGTT time course was
calculated as follows:
xm~
X T
t~1
100   x9m{x0m ðÞ t{ y9m{y0m ðÞ t
    
y0mt
    
T
Where
N xm =mean treatment effect for metabolite m in differences
between day 9 and day 0 (%)
N x9m =mean intensity for metabolite m on day 9 for the
diclofenac treatment group
N x0m =mean intensity for metabolite m on day 0 for the
diclofenac treatment group
N y9m =mean intensity for metabolite m on day 9 for the placebo
group
Table 3. Multivariate data analysis of various metabolic profiling datasets.
Method GC-MS LC-MS LC-MS LC-MS
global polar Lipids FFA
# metabolites 137 130 61 14
PLS-DA
Day 9 vs Day 0 42.00% 53.00% 37.00% 37.00%
n-PLS-DA
Day 0, 2, 4, 7 and 9 57.00% 42.00% 52.50% 47.00%
n-PLS-DA
Day 9 vs Day 0; 0–15–30–45–60–90–120 and 180 min 31.50% 31.50% 21.00% 31.50%
n-PLS-DA after metabolite selection
Day 9 vs Day 0; 0–15–30–45–60–90–120 and 180 min #=77 #=31 #=25 NA
10.50% 5.00% 16.00%
The results of the different multivariate models are expressed as error rates.
Metabolite selection was only applied if the error rate of the original model of the complete dataset was below 35% and the dataset contained more than 50
metabolites. NA, not analyzed.
doi:10.1371/journal.pone.0004525.t003
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N T=total number of time points (t=1 … 8)
Ranges in terms of percentages were calculated per metabolite
as the minimum and maximum value of the treatment effects
calculated per time point. The minimum and maximum value of
treatment effects were calculated per time point per metabolite
and these values were used to determine the ranges of treatment
effects in terms of percentages.
Detailed pathway and biological network analysis was per-
formed in Metacore version 4.3 (GeneGo Inc., St. Joseph, MI,
USA). Only curated interactions were used for biological network
analysis. The following metabolites were not available in Metacore
and therefore not used for pathway and network analysis: 1,2-
diglyceride (C36:2), 2,3,4-trihydroxybutanoic acid and 2-amino-2-
methyl butanoic acid, 1-aminocyclopentanecarboxylic acid. Path-
way maps were edited in Mapeditor (GeneGo Inc., St. Joseph, MI,
USA) version 2.1.0.
Results
Statistical selection of relevant metabolites for diclofenac
treatment
Metabolites that changed due to diclofenac treatment were
identified using various multivariate comparisons. Table 3 shows
the results of these multivariate analyses of the different datasets
derived from the four metabolic profiling platforms.
A comparison of the fasting state metabolomes between the
subjects treated with placebo and diclofenac on day 9 compared to
day 0 resulted in PLS-DA models (Figure 1, analysis a) with high
error rates. This indicated that there was no significant difference
in fasted plasma samples.
Expanding the n-PLS-DA models with the metabolic profiling
data from the plasma samples taken in fasted conditions on
several intermediate days (Figure 1, analysis b) during the
intervention for the various metabolic profiling platforms also
resulted in high error rates. This confirms that differences in
metabolic changes could not be detected between subjects
Table 4. Overview of most discriminating metabolites, their treatment effect and their metabolite response in the OGTT time
course.
Metabolite Treatment effect (%): Diclofenac vs placebo
Mean Range Response type
GC-MS Uric acid 212 218 1 A
1,2-diglyceride (C36:2) 218 228 29A
Proline 9 6 13 A
Isoleucine 218 222 213 A
1-aminocyclopentanecarboxylic acid 22 252 A
Threonine 213 215 211 A
4-Hydroxyproline 259 272 251 A
2,3,4-Trihydroxybutanoic acid 15 9 24 A
Aminoadipic acid 226 243 216 A
Arabitol, ribitol, or xylitol 10 5 13 A
Ornithine 212 220 2 A
Mannose or galactose 10 6 14 A
Palmitoleic acid (C16:1) 23 225 5 A
Palmitic acid (C16:0) 6 213 24 A
LC-MS Isoleucine 223 234 215 A
Glycine 8 B
2-Amino-2-methyl butanoic acid 24 29 21A
5-Oxoproline 14 B
1-Aminocyclopentanecarboxylic acid 269 291 235 A
4-Hydroxyproline 252 261 238 A
Isoleucine & Leucine (not resolved) 28 213 21A
Hippuric acid 63 48 75 A
5-Oxoproline (acetonitrile adduct) 8 B
Aspartic acid 9 B
Glutamic acid 4 B
Citric acid 210 218 6 A
Per analytical platform the metabolites are ranked according to their importance to the model, thus uric acid and isoleucine contributed most in the discrimination
between the treatment groups.
Only identified metabolites are shown in Table 4. The column ‘response type’ refers to Figure 2; metabolites with response type A showed a treatment difference over
the whole time course and metabolites with response type B showed a treatment difference only in the second part of the time course (a response of the metabolite in
the placebo group, whereas no change in the diclofenac treated group). For metabolites with response type B the mean is calculated over the time points with a
treatment difference.
doi:10.1371/journal.pone.0004525.t004
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condition.
Metabolic perturbation by the OGTT improved the meta-
bolic profiling-based differentiation between the treatments. The
n-PLS-DA models on plasma samples taken at 8 point time
course after the glucose administration to subjects on day 9 vs
day 0 (Figure 1, analysis c) resulted in improved error rates. This
was true for all metabolic profiling platforms as compared to
PLS-DA and n-PLS-DA models based on plasma in fasted
conditions, between the control and anti-inflammatory treat-
ment. The n-PLS-DA models for metabolome data from GC-
MS global, LC-MS polar and LC-MS lipids were analyzed
Figure 2. OGTT time course mean metabolite response with standard error on day 9 corrected for concentrations on day 0 for
subjects on placebo and diclofenac treatment. A) for the metabolite isoleucine that contributes to treatment differences over the whole time
course and B) for the metabolite glycine that contributes to treatment differences only in the second part of the time course. Legend to Figure 2:
Dashed line: Diclofenac treated subjects; Solid line: Placebo treated subjects.
doi:10.1371/journal.pone.0004525.g002
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models after metabolite selection for GC-MS global and LC-
MS polar metabolome data resulted in models with error rates
of 10.5% and 5.0% respectively, indicating that the GC-MS
global model and the LC-MS polar model only misclassified
respectively 2 and 1 persons of the total 19. The model of the
LC-MS lipids-dataset resulted in a model with an error rate of
16%, indicating that 3 out of 19 total subjects were misclassified.
Permutation tests were performed on these 3 models to validate
the significance of the treatment differences. The results of the
GC-MS global and LC-MS polar permutation test were ‘good’,
in contrast to the results for the LC-MS lipids model which were
‘moderate’.
Overall, significant metabolic changes due to the treatment
could be detected only in the metabolic profiling data of the
OGTT time course. Only metabolome data from the models with
‘good’ results for the permutation test, thus the LC-MS polar and
GC-MS global models (after metabolite selection), were used for
further interpretation in the statistical analysis.
Metabolite identification
The metabolites with the highest absolute regression coefficients
per time point (thus 0, 15, 30, 45, 60, 90, 120 and 180 minutes)
were selected from the LC-MS polar and GC-MS global n-PLS-
DA models as being most discriminative between subjects treated
with diclofenac and placebo. The intersection of the regression
coefficients per time point resulted in a total of 15 unique
metabolites from the GC-MS global dataset and in a total of 24
unique metabolites from the LC-MS polar dataset for metabolite
identification. Ultimately, 69% of the selected metabolites could be
identified (14 out of 15 in the GC-MS global dataset; 13 out of 24
in the LC-MS polar dataset). Table 4 lists the most discriminating
metabolites that could be identified. Only the identified metab-
olites were used for further interpretation.
Analysis of metabolite response during OGTT time
course
The metabolite response was tracked by plotting the mean
difference between day 9 and day 0 per time point per treatment
group. In general, two different metabolite challenge test
responses were distinguished as illustrated in Figure 2. Most of
the selected metabolites (81%, Table 4) showed a difference in
offset that is constant during the OGTT time course (Figure 2A,
response type A). In other words, these metabolites are
discriminating between the treated and untreated subjects
independent of time during the OGTT time course. This
indicates that only minor differences exist between the treatment
groups and that these differences can only be identified by
repeated measurements. Indeed, time independent PLS-DA
analysis yielded a similar error rate (11%).
Some of the selected metabolites (19%), however, showed only a
contribution to treatment differences in the second part of the
OGTT time course (Figure 2B, response type B). This indicates
that these 4 metabolites only differed between treatments when
challenging the metabolic situation, leading to alterations in
dynamic response to the perturbation. Indeed, time independent
PLS-DA analysis increased the error rate of the LC-MS polar
model (26%).
Furthermore, Table 4 shows the semi-quantified treatment
effects, expressed as the mean change (in %) over time. The
Figure 3. Day 0 insulin response in OGTT time course. Day 0 insulin mean response with standard error is shown in OGTT time course for all
subjects. Insulin concentrations show a maximum at ,65 minutes after glucose intake.
doi:10.1371/journal.pone.0004525.g003
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treatment differences over time (categorized as response type A)
showed a decreased concentration in plasma in response to
diclofenac treatment compared to subjects treated with placebo.
Several amino acids (n=6), organic acids (n=7), carbohydrates
(n=2) and fatty acids & lipids (n=3) were categorized with a
response type A. Some metabolites were identified as being
discriminating between the treatments in data from both analytical
platforms (isoleucine, 1-aminocyclopentanecarboxylic acid and 4-
hydroxyproline), validating their contribution to the differences
between the treatment groups.
All metabolites that specifically showed a dynamic response to
the perturbation (categorized as response type B), showed higher
concentrations in the diclofenac treated group. Based on plots of
mean changes over time, it appeared that mean concentrations of
diclofenac treated subjects remained constant, whereas mean
concentrations of placebo treated subjects dropped during a
specific phase of the time course (Figure 2b). The amino acids
glycine, aspartic acid and glutamic acid and the organic acid 5-
oxoproline were categorized with a response type B.
Discussion
A primary goal of research into lifestyle associated diseases is
to optimize health so that the onset of disease can be prevented
or delayed. In identifying the key changes involved in the
development of lifestyle associated diseases, experimental
approaches have to deal with large inter-individual variety and
the robustness of homeostasis. The current study deliberately
recruited healthy overweight men with slightly increased
inflammation parameters and successfully applied a relatively
mild anti-inflammatory intervention so that only subtle changes
were to be expected. The study authors aimed to demonstrate
that an experimental design using metabolic profiling in concert
with a challenge test is a good strategy for the unraveling of
biomarkers in intervention studies where only subtle changes are
to be expected.
The conventional metabolic profiling approach of measuring
blood samples in fasting conditions – even in a time course –
and the classical biomarkers (i.e. glucose, insulin, sialic acid,
HOMA index, and adiponectin; van Erk et al, in prep) were not
Figure 4. Glutathione synthesis pathway and its connection to glucose and insulin. High levels of glucose inhibit and high levels of insulin
activate glutathione synthesis via the enzyme c-glutamylcysteine synthetase. Legend to Figure 4: Connection arrows with color red represent
inhibition and color green represent activation. Purple hexagons represent metabolites; purple hexagons with white star represent metabolites
measured with one of the metabolic profiling platforms; orange symbols represent enzymes. Red arrows upwards indicate that higher plasma
concentration levels were found in the diclofenac treated group in response to oral glucose tolerance test. Abbreviations: AA, amino acid; Cys-Gly,
cysteinylglycine. These figures were created by using MapEditor version 2.1.0 (GeneGo Inc, St Joseph, MI).
doi:10.1371/journal.pone.0004525.g004
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this study, the subtle metabolic changes resulting from diclofenac
treatment could only be determined using an OGTT time
course. This can have at least two reasons. Firstly, most of the
treatment differences became significant by repeated confirma-
tion of subtle homeostatic alterations in metabolite concentra-
tions (metabolites with response type A) without dealing with
any day-to-day variations like in the ‘long-term’ fasted time
course. Secondly, by perturbing a homeostatic metabolic
situation, metabolite differences with a dynamic response to
the oral glucose tolerance test became visible (response type B
metabolites).
Figure 5. Dynamic response of glutathione synthesis pathway intermediates in OGTT time course. A) glutathione mean response with
standard error on day 9 corrected for concentrations on day 0 for subjects on placebo and diclofenac treatment. Glutathione showed a treatment
difference only in the second part of the time course. B) Cysteinylglycine mean response with standard error on day 9 corrected for concentrations
on day 0 for subjects on placebo and diclofenac treatment. Cysteinylglycine showed a treatment difference only in the second part of the time
course. Legend to Figure 5: Dashed line: Diclofenac treated subjects; Solid line: Placebo treated subjects.
doi:10.1371/journal.pone.0004525.g005
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and transporters [33–41]. CD13 is a broad specificity
aminopeptidase that cleaves specifically the N-terminal bound
neutral amino acids from oligopeptides. The inhibition of the
enzyme aminopeptidase N (CD13) by diclofenac corresponds to
the lower plasma concentrations of several neutral amino acids
such as L-isoleucine, L-threonine, and L-leucine. Such
consistent lowering is reflected in a type A response.
In the current study, the diclofenac intervention applied was
successfully shown by significantly reduced concentrations of
PGE2 (see Materials and Methods). Metabolic profiling revealed
that the diclofenac treatment resulted in lower plasma levels of uric
acid. Elevated serum uric acid levels are positively associated with
metabolic syndrome, insulin resistance and diabetes type II [42,43]
and has been proposed as risk factor for hypertension and
cardiovascular diseases [44,45]. Subsequently, elevated levels of
uric acid are associated with inflammation and oxidative stress
[42,43,46]. The current results suggest that inhibition of
cyclooxygenase mediated inflammation (shown by significantly
reduced concentrations of PGE2) could be associated with reduced
concentrations of uric acid and therefore might lead to a reduction
of risk on several metabolic diseases. However, this needs to be
further explored.
Most interestingly in this study are the metabolites that
showed a differential response between the treatments groups to
the OGTT (metabolites identified with a response type B). All
metabolites with response type B showed the largest difference
between the treatments at time point 90 and/or 120 minutes
after intake of glucose. Insulin peaks at an average of 65 minutes
after glucose intake (Figure 3). This suggests that differences in
response to the OGTT may be attributed to the action of
insulin.
Of the 26 peaks that were most discriminative in the nPLS-
DA models (Table 3), five peaks were found with this response
type B profile of which two were annotated as 5-oxoproline and
the others as the amino acids glycine, aspartic acid and glutamic
acid. Three of these - 5-oxoproline, glycine and glutamic acid -
are known to be involved in the glutathione synthesis pathway
(Figure 4). Therefore, the response of other intermediates in the
glutathione synthesis pathway was also studied. It appeared that
glutathione and cysteinylglycine showed a similar dynamic
response to the OGTT as the other type B responders
(Figure 5), with the exception of plasma cysteine. Figure 4
provides and overview of the glutathione synthesis pathway and
its relationship to glucose and insulin. Higher clearance of
plasma L-5-oxoproline is known in case of lower GSH synthesis
[47]. GSH synthesis is predominantly regulated by activity of c-
glutamylcysteine synthetase (GCS) and availability of the rate-
limiting substrate cysteine [48]. Interestingly, it is known that
insulin action increases and glucose decreases the regulation of
GSH synthesis by GCS [48–50]. In this study, the average
plasma glutathione concentrations declined to their minimum
concentration at 60 minutes after glucose intake and increased
again at 90 to 120 minutes after glucose intake (Figure 6). In the
current study, the control group showed significant lower
concentrations of glutathione synthesis pathway intermediates
at 90 to 120 minutes after glucose intake compared to diclofenac
treated subjects. This might indicate that diclofenac treatment
resulted in a higher GSH synthesis response after the glucose
bolus, which might be related to altered insulin signaling with
Figure 6. Day 0 glutathione response in OGTT time course. Day 0 glutathione mean response with standard error is shown in OGTT time
course for all subjects. Glutathione showed declined concentrations in the first part of the time course with a minimum concentration at 60 minutes
after glucose intake. In the second part of the time course concentrations increase again.
doi:10.1371/journal.pone.0004525.g006
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inhibition of cyclooxygenase-2 results in increased insulin
sensitivity in overweight or obese subjects [51]. However, no
differences were found in classical insulin sensitivity indexes
(HOMA index, ISIcomp, MCRest and Gutt-index) between
diclofenac and placebo treated subjects in this study. A possible
explanation is that the combination of multiple metabolites as
biomarker in concert with an oral glucose tolerance test
allows for an earlier detection of changes in insulin sensitivity,
however this is speculation at this stage and should be further
explored.
This first exploratory study shows that subtle metabolic changes
resulting from an anti-inflammatory treatment could only be
determined using a metabolic perturbation test in a well-designed
clinical study using metabolic profiling analysis. Differences in
dynamic response to the challenge (response type B metabolites)
might be derived from insulin regulated processes such as the
insulin regulated glutathione synthesis pathway. Our study
demonstrates that the use of metabolic profiling in concert with
a challenge test may open new avenues for biomarker discovery
that could be useful in developing preventive strategies for lifestyle
associated diseases.
Supporting Information
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